Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -106.87% is 44% above its 4-year average of -190.59%, near the high end of its 4-year range (-420.01%–-2.68%).
As of the fiscal period ended Tuesday, June 30, 2026. 17.80% above its 12-month average of -130.01%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -106.87%.
RETURN ON EQUITY (ROE)
-106.87%
RETURN ON EQUITY (ROE) AVG TTM
-130.01%
RETURN ON EQUITY (ROE) AVG 3Y
-235.32%
RETURN ON EQUITY (ROE) AVG 5Y
-190.59%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+17.80%
CURRENT VS 3Y AVG
+54.59%
CURRENT VS 5Y AVG
+43.93%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-41.56%
median of 737 covered companies
CURRENT VS SECTOR MEDIAN
-157.14%
vs the sector median at left
Biofrontera Inc.
Market Cap
$11.43M
Return on Equity (ROE)
-106.87%
TTM Avg
-130.01%
3Y Avg
-235.32%
5Y Avg
-190.59%
Market Cap
$11.32M
Return on Equity (ROE)
-37052.06%
TTM Avg
-237.80%
3Y Avg
-258.91%
5Y Avg
-310.30%
Market Cap
$11.56M
Return on Equity (ROE)
-102.40%
TTM Avg
-97.28%
3Y Avg
-110.13%
5Y Avg
-94.77%
Market Cap
$11.12M
Return on Equity (ROE)
-65.18%
TTM Avg
-26.62%
3Y Avg
-94.28%
5Y Avg
-90.35%
Market Cap
$11.04M
Return on Equity (ROE)
-214.92%
TTM Avg
-46.13%
3Y Avg
-156.76%
5Y Avg
-652.77%
Market Cap
$10.91M
Return on Equity (ROE)
-506.63%
TTM Avg
-300.20%
3Y Avg
-300.20%
5Y Avg
-300.20%
Market Cap
$10.84M
Return on Equity (ROE)
-477.54%
TTM Avg
-207.60%
3Y Avg
64.51%
5Y Avg
-22.91%
Market Cap
$10.65M
Return on Equity (ROE)
-177.35%
TTM Avg
-89.62%
3Y Avg
-75.99%
5Y Avg
-59.80%
Market Cap
$12.19M
Return on Equity (ROE)
-97.47%
TTM Avg
-90.15%
3Y Avg
-205.18%
5Y Avg
-136.35%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Biofrontera Inc. (BFRI) | $11.43M | -106.87% | -130.01% | -235.32% | -190.59% |
| Adial Pharmaceuticals, Inc. (ADIL)vs › | $11.32M | -37052.06% | -237.80% | -258.91% | -310.30% |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.56M | -102.40% | -97.28% | -110.13% | -94.77% |
| Kiora Pharmaceuticals, Inc. (KPRX)vs › | $11.12M | -65.18% | -26.62% | -94.28% | -90.35% |
| BioVie Inc. (BIVI)vs › | $11.04M | -214.92% | -46.13% | -156.76% | -652.77% |
| Caring Brands, Inc. (CABR)vs › | $10.91M | -506.63% | -300.20% | -300.20% | -300.20% |
| Cerenome, Inc. (CNSY)vs › | $10.84M | -477.54% | -207.60% | 64.51% | -22.91% |
| Lisata Therapeutics, Inc. (LSTA)vs › | $10.65M | -177.35% | -89.62% | -75.99% | -59.80% |
| IRIDEX Corporation (IRIX)vs › | $12.19M | -97.47% | -90.15% | -205.18% | -136.35% |
| Tvardi Therapeutics, Inc. (TVRD)vs › | $10.60M | -310.94% | 727.99% | 459.17% | 300.20% |
ROE
-106.9%
ROA
-26.4%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -106.87% |
| 2026-03-31 | -182.62% |
| 2025-12-31 | -100.53% |
| 2024-12-31 | -400.61% |
| 2024-09-30 | -232.13% |
| 2024-06-30 | -123.82% |
| 2023-12-31 | -420.01% |
| 2023-06-30 | -315.99% |
| 2023-03-31 | -81.66% |
| 2022-12-31 | -2.68% |
| 2022-09-30 | -54.70% |
| 2022-06-30 | -149.75% |
| 2022-03-31 | -164.31% |
| 2021-12-31 | -332.62% |
| 2021-03-31 | -454.10% |
| 2020-12-31 | -188.52% |
